Project Grant K24HL180320
- This federal Project Grant award, valued at $162,703.00 and granted by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to determine whether streamlined, standardized blood pressure (BP) measurement protocols can be implemented in primary care settings. The project builds on the Alabama Cardiovascular Cooperative's Heart Health Improvement Project and seeks to improve the accuracy and efficiency of BP measurements to inform treatment decisions...
- The University of Alabama at Birmingham (UAB) was awarded a $539,342 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on the circadian mechanisms governing cardiac growth. The project aims to investigate how the cardiomyocyte circadian clock regulates cardiac processes, particularly the branched chain amino acid catabolism and mTOR activation during the active and sleep periods. This research seeks to advance...
- The University of Alabama at Birmingham (UAB) received a $222,750 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to develop a clinical decision support questionnaire to identify barriers to blood pressure control. The project aims to address the high rates of uncontrolled hypertension in the U.S., which is a leading cause of morbidity, mortality, and substantial healthcare costs. The award, with a performance period from July...
- This $734,722 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a randomized controlled clinical trial to assess the impact of disclosing systolic blood pressure polygenic risk scores on blood pressure control, healthy lifestyle adherence, and cardiometabolic health among 300 hypertensive adults aged 18-55 in the United States. The study aims to evaluate whether providing individuals with information about their...
- The University of Alabama at Birmingham (UAB) received a $637,732 project grant from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on improving the cardiac microenvironment as a novel strategy against diabetic ischemic heart failure. The project aims to leverage insights from cellular secretome research to transform treatment strategies for diabetic ischemic heart failure. Specifically, the research will investigate how...
- This Project Grant award, valued at $249,000.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The grant supports a research project at the University of Alabama at Birmingham (UAB) titled "Early Life Stress and Cardiovascular Disease Risk: Identifying the Role of Microbial Metabolites." The project aims to investigate how early life stress affects the gut microbiome and related...
- This $165,364 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to integrate novel contextual and genomic blood pressure measures to enhance cardiovascular disease prediction and management in young adults aged 18-39 years. The key products and services to be delivered under this 2-year award include: Identifying novel ambulatory blood pressure patterns that capture dynamic responses to everyday factors and...
- The federal Project Grant award of $535,556.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Alabama at Birmingham (UAB). The funding will support a research project to investigate the role of a novel histone modification, H3T32 O-GlcNAc, in endothelial cell dysfunction and atherosclerosis. The 5-year project aims to elucidate the epigenetic features of this histone modification under...
- This Project Grant award, valued at $498,991.40, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas, Fayetteville. The goal is to engineer microphysiological systems with tight oxygen control to investigate the molecular pathways activated in oxygen gradients and the resulting effects on cardiomyocyte function, in order to obtain a comprehensive understanding of the cardiac response to hypoxic...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to discover novel biomarkers and biological mechanisms underlying early-stage heart failure (HF). The $147,486 award to Duke University will support the development of an automated computational phenotype to identify early-stage HF, which will then be applied to large population cohorts. The research aims to leverage multi-omics data integration and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $132,623.00 in funding to the University of Alabama at Birmingham (UAB) for the project "Mentored Patient-Oriented Research in Natriuretic Peptide System Based Precision Cardiometabolic Health". The award period runs from Sep 1, 2025 to Aug 31, 2030. The key products and services under this award include: 1) Mentoring and training for early-career researchers in areas such as clinical epidemiology, big data analysis, clinical trial design, genomic studies, and precision medicine to develop well-rounded physician-scientists; 2) Research focused on assessing genetic determinants of natriuretic peptide levels, unraveling pathways linking natriuretic peptides to cardiometabolic disease, and developing targeted approaches centered on the natriuretic peptide system to treat cardiometabolic conditions; and 3) Epidemiological studies on cardiovascular health disparities and clinical outcomes in cardiovascular diseases.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $132.6k | 8/27/25 |